Dr. Lal PathLabs Limited Reports Earnings Results for the First Quarter Ended June 30, 2023
July 27, 2023 at 04:58 am EDT
Share
Dr. Lal PathLabs Limited reported earnings results for the first quarter ended June 30, 2023. For the first quarter, the company reported sales was INR 5,410 million compared to INR 5,027 million a year ago. Revenue was INR 5,554 million compared to INR 5,110 million a year ago.
Net income was INR 826 million compared to INR 577 million a year ago. Basic earnings per share from continuing operations was INR 9.95 compared to INR 6.97 a year ago. Diluted earnings per share from continuing operations was INR 9.93 compared to INR 6.96 a year ago.
Dr. Lal PathLabs Limited is an India-based company that is engaged in providing diagnostic and related healthcare tests and services. The Company is engaged in the business of running laboratories for carrying out pathological investigations of various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It offers a range of tests by condition, which includes allergy, diabetes, health checkups, viral infections, fever, heart diseases, hypertension, cancer, abortions, anemia, arthritis, breast cancer, diphtheria, disorder of the liver, disorders of bone, drugs of abuse, infertility, lymphoma, tuberculosis, ovarian cancer, osteoporosis, multiple sclerosis, muscular disorder, and viral infections. The Companyâs subsidiaries include Paliwal Diagnostics Private Limited, Paliwal Medicare Private Limited, and Dr. Lal PathLabs Nepal Private Limited.
DR. LAL PATHLABS LIMITED 
